S 488210

Drug Profile

S 488210

Alternative Names: RSC-488210; S-488210

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoTherapy Science
  • Developer Shionogi
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer

Most Recent Events

  • 06 Dec 2017 Phase-II clinical trials in Head and neck cancer (Inoperable/Unresectable, Locally recurrent, Metastatic disease, Second-line therapy or greater) in Belgium (SC) before December 2017 (Shionogi pipeline, December 2017)
  • 06 Dec 2017 Phase-II clinical trials in Head and neck cancer (Inoperable/Unresectable, Locally recurrent, Metastatic disease, Second-line therapy or greater) in Germany (SC) before December 2017 (Shionogi pipeline, December 2017)
  • 31 Aug 2015 S 488210 is still in phase I/II trials for Head and neck cancer in Belgium and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top